# Exploring the Endocannabinoid System in Mental Health Treatment Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-mental-health-research/ > **Published:** 2026-04-25T11:18:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:54:53-04:00 > **Clinical Summary:** Explore the latest endocannabinoid system mental health research and its implications for psychiatric treatment and clinical studies. --- #### Clinical Takeaway Clinical Takeaway: GLP-1 receptor agonists show no consistent causal relationship with improvement or worsening of common mental illnesses based on genetic analysis, suggesting that observed mental health changes in patients taking these medications may result from weight loss effects or other mechanisms rather than direct drug action on psychiatric conditions. Current evidence does not support using GLP-1 agonists as primary treatment for mental illness, though they may benefit mental health indirectly through metabolic improvements in patients with obesity and comorbid psychiatric conditions. ### #28 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. **Citation:** Xiang Longgang et al. *Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.* International journal of molecular sciences. 2025. PMID: 40141382. **Study type:** Journal Article, Meta-Analysis  |  **Topic area:** Autism  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/), major depressive disorder, post-traumatic stress disorder, schizophrenia, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/). Our study provides useful information for understanding the neuropsychiat  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40141382/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942543/)[DOI ↗](https://doi.org/10.3390/ijms26062741) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Clinical Research Guide](https://cedclinic.com/glp-1-receptor-agonists-mental-health-evidence-overview/) A comprehensive guide to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), detailing its therapeutic potential and current scientific findings. [Read the Guide](https://cedclinic.com/glp-1-receptor-agonists-mental-health-evidence-overview/) [Endocannabinoid System & GLP-1 Receptor Mental Health Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) Explore evidence linking the endocannabinoid system and GLP-1 receptor in mental health, highlighting recent research outcomes. [Explore Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) [Endocannabinoid System Psychosis Risk: Clinical Research Guide](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression-guide/) An in-depth clinical research guide examining the relationship between the endocannabinoid system and psychosis risk. [View Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression-guide/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Exploring%20the%20Endocannabinoid%20System%20in%20Mental%20Health%20Treatment%20Research&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-mental-health-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-mental-health-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Exploring%20the%20Endocannabinoid%20System%20in%20Mental%20Health%20Treatment%20Research%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-mental-health-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).